Cargando…

Intrinsic molecular subtypes of HER2+ breast cancer

Detalles Bibliográficos
Autores principales:	Prat, Aleix, Pascual, Tomás, Adamo, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650264/ https://www.ncbi.nlm.nih.gov/pubmed/29088709 http://dx.doi.org/10.18632/oncotarget.20629

Ejemplares similares

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
por: Prat, Aleix, et al.
Publicado: (2014)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes
por: Prat, Aleix, et al.
Publicado: (2013)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
por: Fernand ez-Martinez, Aranzazu, et al.
Publicado: (2017)

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
por: Prat, Aleix, et al.
Publicado: (2015)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay
por: Desai, Neelam V., et al.
Publicado: (2018)

Intrinsic subtypes and bladder cancer metastasis
por: McConkey, David J., et al.
Publicado: (2016)

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status
por: Prat, Aleix, et al.
Publicado: (2014)

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
por: Bueno Muiño, Coralia, et al.
Publicado: (2022)

Deconstructing the molecular portraits of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
por: Schettini, F., et al.
Publicado: (2023)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients
por: Lee, Moo Hyun, et al.
Publicado: (2016)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022)

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
por: Díaz-Gil, Laura, et al.
Publicado: (2021)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype
por: Capasso, Immacolata, et al.
Publicado: (2014)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes
por: Jönsson, Jenny-Maria, et al.
Publicado: (2014)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
por: Sanz-Moreno, Adrián, et al.
Publicado: (2021)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Making Breast Cancer Molecular Subtypes Robust?
por: Staaf, Johan, et al.
Publicado: (2014)

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
por: Gavilá, Joaquín, et al.
Publicado: (2019)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
por: Ding, Yi, et al.
Publicado: (2018)

Intrinsic subtypes in Ethiopian breast cancer patient
por: Desalegn, Zelalem, et al.
Publicado: (2022)

Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer
por: Miyan, M., et al.
Publicado: (2016)

Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status
por: Rossing, Maria, et al.
Publicado: (2021)

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
por: Prat, Aleix, et al.
Publicado: (2021)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1quiter0a2377c3vnqa7eh7cip